ライフサイエンスコーパス: octreotide

1 er injection of 111-185 MBq of (99m)Tc-HYNIC-octreotide.

2 esophageal varices 7(41.2%) did not receive octreotide.

3 r (111)In-diethylenetriaminepentaacetic acid-octreotide.

4 t (111)In-diethylenetriaminepentaacetic acid-octreotide.

5 patches, biologic sealants, or prophylactic octreotide.

6 h (111)In-diethylenetriaminepentaacetic acid-octreotide.

7 dium-chain triglyceride supplementation, and octreotide.

8 were put on total parenteral nutrition plus octreotide.

9 adjuvant trial of tamoxifen with or without octreotide.

10 on in a dose-dependent manner, comparable to octreotide.

11 symptoms were worse in patients treated with octreotide.

12 ncies (IC(50), 0.1-1.0 microM) comparable to octreotide.

13 tion-approved radiopharmaceutical indium 111 octreotide.

14 a dose-dependent manner by administration of octreotide.

15 hose developing in acromegalics treated with octreotide.

16 c meeting abstracts, and the manufacturer of octreotide.

17 lso appears to be more accurate than (111)In-octreotide.

18 ed with historical controls not treated with octreotide.

19 r (111)In-diethylenetriaminepentaacetic acid-octreotide.

20 s to many more sst2 sites than (125)I-Tyr(3)-octreotide.

21 atively stable somatostatin analogs, such as octreotide.

22 ng (68)Ga-DOTATATE to be more sensitive than octreotide.

23 Patients received octreotide 0.5 mg subcutaneously tid.

24 o (4.17, 1.37-12.50) and over midodrine plus octreotide (10.00, 1.49-50.00) for this outcome.

25 located in a double-blind fashion to receive octreotide (100 microg, administered subcutaneously on d

26 In-diethylenetriaminepentaacetic acid (DTPA)-octreotide ((111)In-DTPA-OC) as a basis for implementing

27 n-labeled diethylenetriaminepentaacetic acid-octreotide ((111)In-DTPA-OC).

28 h a single radioligand, either (125)I-Tyr(3)-octreotide, (125)I-GLP-1(7-36)amide, or (125)I-GIP(1-30)

29 ]FDG, [(18)F]AlF-NOTA-RGDfK, [(18)F]AlF-NOTA-octreotide ([(18)F]AlF-NOTA-OC), [(18)F]AlF-NOTA-NOC, [(

30 agement in 51%); and comparison with (111)In-octreotide (2 papers, sensitivity of DOTATOC on a per-le

31 d subcutaneously on day 1, followed by depot octreotide, 20 mg, administered intramuscularly on days

32 istorical control group that did not receive octreotide (24% versus 43%; P=0.04).

33 glucagon, we infused the somatostatin analog octreotide (30 ng x kg(-1) x min(-1)) (with growth hormo

34 mg per kilogram of body weight per day) and octreotide (35 mug per kilogram per day).

35 zacyclotetradecane-1,4,8,11-tetraacetic acid-octreotide ((64)Cu-TETA-OC) and (111)In-labeled diethyle

36 r PET tracers such as [(68)Ga-DOTA,1-Nal(3)]-octreotide ((68)Ga-DOTANOC) and [(68)Ga-DOTA,Tyr(3)]-oct

37 , (68)Ga-DOTATATE, and [(68)Ga-DOTA,1-Nal(3)]octreotide ((68)Ga-DOTANOC), plays an important role in

38 erapeutic and early interim (68)Ga-DOTA-Tyr3-octreotide ((68)Ga-DOTATOC) positron emission tomography

39 with PLE included spironolactone (21 [68%]), octreotide (7 [21%]), sildenafil (6 [19%]), fenestration

40 Tyr(3)]octreotide or [(177)Lu-DOTA(0),Tyr(3)]octreotide ((90)Y- or (177)Lu-DOTATOC, respectively) and

41 acyclododecane-tetraacetic acid modified Tyr-octreotide ([(90)Y-DOTA]-TOC) or with cycles alternating

42 d, double-blind, placebo-controlled trial of octreotide, a long-acting somatostatin analogue.

43 Octreotide, a somatostatin analog, is proposed to reduce

44 onary effects of serotonin and bradykinin is octreotide, a somatostatin analogue.

45 Proof of principle studies with octreotide, a somatostatin receptor agonist, demonstrate

46 Octreotide, a somatostatin receptor ligand that targets

47 Finally, octreotide abrogated the activation of phosphorylation o

48 s incubated with GH and SRIF, or with GH and octreotide, abrogated the inhibitory effect on GH-induce

49 ) has been used in Sandostatin(R) LAR Depot (octreotide acetate for injectable suspension) approved b

50 ed either 1 mL 0.9% saline or 1 mL (100 mug) octreotide acetate subcutaneously followed by a standard

51 After octreotide, ad libitum calorie intake increased among ES

52 a hospitalization for GI bleed and received octreotide after discharge.

53 i-inflammatory and anti-apoptotic effects of octreotide after HIR.

54 ents who received secondary prophylaxis with octreotide after their index GI bleed from 2009 to 2015.

55 Moreover, octreotide alleviated inflammation and apoptosis in the

56 Octreotide alone has modest activity in patients with oc

57 Responding patients continued to receive octreotide alone; patients with progressive disease were

58 ) were observed (four partial responses with octreotide alone; the remainder with octreotide plus pre

59 Octreotide also inhibited GH-stimulated IGF-I protein co

60 r interferon alfa-2b (IFN-alpha-2b) added to octreotide among patients with advanced NETs.

61 Thus, we assessed cAMP levels and evaluated octreotide (an analogue of somatostatin known to inhibit

62 Octreotide, an SSTR agonist, has been used to suppress t

63 Recently, (57)Co-labeled DOTATOC, an octreotide analog, was shown to have the highest affinit

64 Radiolabeled octreotide analogs are most successfully being applied t

65 the biologic effects of novel cobalt-labeled octreotide analogs targeting the somatostatin receptor t

66 No direct comparison of octreotide and (68)Ga-DOTATATE imaging for diagnosis and

67 in analogue that has a longer half-life than octreotide and a broader binding profile, decreases panc

68 nt continues to be treated successfully with octreotide and amlodipine.

69 TATATE for safety and efficacy compared with octreotide and conventional imaging to determine whether

70 d staging of NETs compared with (111)In-DTPA-octreotide and conventional imaging.

71 Octreotide and lanreotide are further being described fo

72 Micromolar concentrations of octreotide and NISAs are necessary for antiangiogenic ef

73 Use of octreotide and seeking specialist advice early for patie

74 Octreotide and somatostatin-28 cell membrane binding aff

75 onists and multireceptor agonists, including octreotide and somatostatin-28.

76 of liver cysts in mice treated with combined octreotide and sorafenib.

77 iscovery of the antiangiogenic properties of octreotide and the overexpression of tyrosine kinase rec

78 specificity, comparison studies with (111)In-octreotide, and change of management studies.

79 ted the use of noradrenaline, midodrine plus octreotide, and dopamine plus furosemide over placebo to

80 de, interferon alpha-2b, letrozole, Y-27632, octreotide, and human growth hormone, all delivered at c

81 oduce the effects of the drugs verapamil and octreotide, and we show that the experimental CF drug VX

82 in 18%, 31%, 31%, and 21% of patients in the octreotide arm, respectively, and in 25%, 32%, 22%, and

83 Multiple uncontrolled case series describe octreotide as an effective treatment, and octreotide usa

84 ansfer in tumor-bearing animals with (111)In-octreotide at doses similar to those already used in hum

85 ved pazopanib 800 mg orally once per day and octreotide at their preprotocol dosage.

86 On positive uptake on octreotide-based PET/SPECT imaging, treatment is usually

87 lso a significant reduction in the amount of octreotide being used after completion of (90)Y-SMT 487

88 oendocrine tumors from patients treated with octreotide but that a striking variability exists in the

89 ive uptake studies showed that blocking with octreotide caused a dose-dependent reduction in (64)Cu-M

90 ment, suppression of glucagon secretion with octreotide caused a progressive fall in plasma glucose c

91 als are underway to evaluate the efficacy of octreotide, celecoxib, and candesartan on DR.

92 wley rats were pretreated with octreotide or octreotide combined with 3-methyladenine (autophagy inhi

93 Octreotide combined with emodin or 4,5,6,7-tetrabromoben

94 e potential bioimaging applications of COUPY-octreotide conjugates were demonstrated by confocal micr

95 COUPY-octreotide conjugates were found stable in cell culture

96 using either the anti-HA antibody or (111)In-octreotide correlated with biodistribution and imaging s

97 onships of a series of rhenium (Re)-cyclized octreotide derivatives are described.

98 nsitivity of PET imaging with (68)Ga-labeled octreotide derivatives for the detection and staging of

99 Re-cyclization of the octreotide derivatives led to structural perturbations o

100 (111)In-Octreotide detected the SSTR2 portion of the fusion prot

101 Octreotide did not affect baseline perfusion pressures (

102 Octreotide did not alter the breakpoint among ES or cont

103 As administered in this study, octreotide did not decrease diarrhea during pelvic radia

104 receptor occupancy in NETs, thereby allowing octreotide dosing to be optimized readily in individual

105 lguanidine (MIBG) and (90)Y-DOTA-D-Phe1-Tyr3-octreotide (DOTATOC) have been used as radiotherapeutic

106 in, [Tyr(4)]-neurotensin(8-13), and [Tyr(3)]-octreotide, each of which has a different position for t

107 synthesis, which allowed for the labeling of octreotide either through amide-bond formation or by CuA

108 rs involving activation of protein kinase C, octreotide exerts a local vasoconstrictive effect on vas

109 Octreotide exerts a protective effect in hepatic ischemi

110 Octreotide exhibits an integrated effect of both recepto

111 Acute or chronic octreotide exposure at low or high doses did not signifi

112 ents with negative or equivocal (111)In-DTPA-octreotide findings, (68)Ga-DOTATATE PET identifies addi

113 ro exposure of cells to low or high doses of octreotide for 1-14 d does not result in the development

114 Both donors and recipients were treated with octreotide for 5 days perioperatively.

115 transfected cells were injected with (111)In-octreotide for biodistribution and imaging studies.

116 We identified randomized trials of octreotide for variceal hemorrhage from computerized dat

117 of novel medical treatments (eg, long-acting octreotide formulations, mTOR inhibitors, and GLP-1 rece

118 oncentration during a 180-minute infusion of octreotide, glucose, and insulin was used to stratify pa

119 concentration in response to an infusion of octreotide, glucose, and insulin, and degree of adiposit

120 ing the last 30 min of a 180-min infusion of octreotide, glucose, and insulin.

121 ractically unchanged (+0.25%+/-7.53%) in the octreotide group but increased by 8.61%+/-10.07% in the

122 ver volume decreased by 4.95%+/-6.77% in the octreotide group but remained practically unchanged (+0.

123 patient-reported symptoms were worse in the octreotide group, including nocturnal bowel movements (7

124 device receiving secondary prophylaxis with octreotide had a significantly lower GI bleed recurrence

125 Octreotide had comparable efficacy to immediate scleroth

126 Although octreotide had similar inhibiting potency (picomolar) fo

127 ian target of rapamycin, in combination with octreotide has demonstrated encouraging antitumor activi

128 pecific therapy with somatostatin analogues (octreotide) has replaced older less specific drugs (e.g.

129 Studies of octreotide have not demonstrated a consistent benefit in

130 atostatin receptor scintigraphy, long-acting octreotide, hepatic artery embolization, endoscopic muco

131 SSTR subtypes that bind octreotide (ie, SSTR2, SSTR3, and SSTR5) were expressed

132 Octreotide improved control of esophageal variceal hemor

133 CK2 inhibitors with the somatostatin analog octreotide in a mouse model of oxygen-induced retinopath

134 imal PET/CT imaging results of (86)Y-CHX-A''-octreotide in a somatostatin receptor-positive tumor-bea

135 tudy was designed to investigate the role of octreotide in AKI after HIR.

136 performed with (125)I-JR11 and (125)I-Tyr(3)-octreotide in cancers from prostate, breast, colon, kidn

137 yristolated (1 muM) and in mice treated with octreotide in combination with sorafenib, the paradoxica

138 with that of the sst2 agonist (125)I-Tyr(3)-octreotide in large varieties of non-NET and NET.

139 tudy of the efficacy of pazopanib with depot octreotide in patients with advanced NETs.

140 tionale for assessing the potential value of octreotide in the treatment of PCLDs.

141 Common adverse events with bevacizumab and octreotide included hypertension (32%), proteinuria (9%)

142 rols, P = 0.63 CONCLUSIONS: Somatostatin and octreotide increase the likelihood of fistula closure.

143 Additionally, octreotide induced autophagy and autophagy inhibition wi

144 Octreotide induced sustained SSTR2A/beta-arrestin intera

145 t is a pathogenic factor in the formation of octreotide-induced gallstones.

146 We found that somatostatin analogue octreotide induces apoptosis in VHL-HB stromal cells in

147 Assuming that chronic exposure to octreotide induces tachyphylaxis, we hypothesized that c

148 is interesting that in the WT preparations, octreotide inhibited both low- and high-threshold mechan

149 In vitro, octreotide inhibited cAMP levels by 35% and reduced cyst

150 rations in response to a 180-min infusion of octreotide, insulin, and glucose.

151 e therapy with antioestrogens and androgens, octreotide, interferon, and both arterial and systemic c

152 hat the antiangiogenic activity of NISAs and octreotide is mediated by an overall much less efficient

153 Octreotide is not indicated for prevention of diarrhea d

154 (111)In-Octreotide is used clinically to locate tumors overexpre

155 Somatostatin, but not octreotide, is likely to be effective in the prevention

156 on a per-lesion basis was 100%, for (111)In-octreotide it was 78.2%; specificity was not available).

157 clude somatostatin receptor ligands (such as octreotide, lanreotide and pasireotide), dopamine agonis

158 SST-14, SST-28, and peptide analogs (octreotide, lanreotide, and vapreotide) stimulated clath

159 SSTR2A activated by SST-28, octreotide, lanreotide, or vapreotide was retained withi

160 nts were randomly assigned to treatment with octreotide LAR 20 mg every 21 days with either bevacizum

161 d (30 patients) or 10 mg/d (30 patients) and octreotide LAR 30 mg every 28 days.

162 irinotecan were randomly assigned to receive octreotide LAR 30 mg intramuscularly every 4 weeks (expe

163 a dose of 30 mg) ((177)Lu-Dotatate group) or octreotide LAR alone (113 patients) administered intramu

164 ficantly higher response rate than high-dose octreotide LAR among patients with advanced midgut neuro

165 Coadministration of octreotide LAR and everolimus did not impact exposure to

166 domly assigned 42 patients in a 2:1 ratio to octreotide LAR depot (up to 40 mg every 28+/-5 days) or

167 Treatment with octreotide LAR did not prevent or reduce the severity of

168 This study could not prove the efficacy of octreotide LAR in the prevention of CID.

169 No benefit from octreotide LAR was identified in terms of need for diarr

170 nd safety of long-acting release octreotide (octreotide LAR) for the prevention of CID in this popula

171 aily everolimus, with or without concomitant octreotide LAR, demonstrates antitumor activity as measu

172 mg/d was well tolerated in combination with octreotide LAR, with promising antitumor activity.

173 the disease eventually becomes refractory to octreotide, leaving no proven treatment options.

174 n = 115; stratum 2: everolimus 10 mg/d plus octreotide long-acting release [LAR], n = 45).

175 ty of the long-acting somatostatin analogues octreotide long-acting release and lanreotide for advanc

176 d progression-free survival versus high-dose octreotide long-acting release in a phase III clinical t

177 y of everolimus (RAD001) in combination with octreotide long-acting repeatable (LAR) in patients with

178 fusions, plus best supportive care including octreotide long-acting repeatable [LAR] administered int

179 e upper normal limit) and had received 30 mg octreotide long-acting repeatable or 120 mg lanreotide (

180 In vivo, octreotide lowered cAMP content in cholangiocytes and se

181 arker, and combination of CK2 inhibitors and octreotide may be a promising future treatment for proli

182 f autophagy may be potentially linked to the octreotide mediated Akt/mTOR/p70S6K pathway deactivation

183 The combination of octreotide, midodrine, and albumin (triple therapy) is u

184 rs obtained from 10 octreotide-treated and 7 octreotide-naive patients.

185 All seven octreotide-naive tumors displayed exclusively nonphospho

186 e vasoactive drugs (terlipressin, midodrine, octreotide, noradrenaline, and dopamine; alone or in com

187 n; vasoconstrictor; terlipressin; midodrine; octreotide; noradrenaline; and norepinephrine.

188 retion may contribute to a variation in SSTR octreotide occupancy with a given dose among different p

189 ffect of GDNF was mimicked by the SOM analog octreotide (OCT) and required intact SOM neuronal pools.

190 ing CTX with a somatostatin analogue such as octreotide (OCT) is beneficial.

191 In humans, the SOM stable analogue octreotide (OCT) is used to treat opioid-resistant pain.

192 To this end, the SST analogue octreotide (OCT) was microinjected into the striatum pri

193 [kg x min]) followed by 3-h infusion of GCG, octreotide (OCT), and insulin (INS) for basal replacemen

194 hitosan (CMCS) on inhibition of acylation of octreotide (Oct), salmon calcitonin (sCT), and human par

195 argeting somatostatin receptors (SSTRs) with octreotide (OCT; a somatostatin analog that preferential

196 e efficacy and safety of long-acting release octreotide (octreotide LAR) for the prevention of CID in

197 (odds ratio 1.49 per point, P < 0.00001) and octreotide (odds ratio 3.30, P < 0.00001).

198 suring the effect of the somatostatin analog octreotide on appetitive behavior among patients after E

199 Effects of octreotide on cAMP levels and cyst expansion were studie

200 The effects of octreotide on hepatic and renal cystogenesis were invest

201 (AAVP) vector displaying biologically active octreotide on the viral surface for ligand-directed deli

202 e shown a complex mechanism of the effect of octreotide on tumors.

203 The effect of octreotide on vascular tone in the superior mesenteric a

204 sstr agonists, such as [(90)Y-DOTA(0),Tyr(3)]octreotide or [(177)Lu-DOTA(0),Tyr(3)]octreotide ((90)Y-

205 diagnostic accuracy of (68)Ga-DOTATATE with octreotide or conventional imaging for pulmonary or gast

206 ys for 24 weeks, or continued treatment with octreotide or lanreotide (active control).

207 stratified according to previous treatment (octreotide or lanreotide) and growth hormone concentrati

208 acting release compared with active control (octreotide or lanreotide) in patients with inadequately

209 icacy compared with continued treatment with octreotide or lanreotide, and could become the new stand

210 the first-generation somatostatin analogues octreotide or lanreotide.

211 d by incubating peptide solutions of 0.2-4mM octreotide or leuprolide acetate salts in a 0.1M HEPES b

212 ale Sprague-Dawley rats were pretreated with octreotide or octreotide combined with 3-methyladenine (

213 ive agonist at lower concentrations than for octreotide or somatostatin-28, whereas SST5 did not inte

214 the use of terlipressin over midodrine plus octreotide (OR 26.25, 95% CI 3.07-224.21) to reverse hep

215 drain placement (OR 5.51), and prophylactic octreotide (OR 3.09).

216 kephalin](OTf)(2) and [(eta(6)-Cp*Rh-Tyr(3))-octreotide](OTf)(2).

217 These results favor octreotide over vasopressin/terlipressin in the control

218 Use of octreotide (p<0.0001) and chemotherapy (p=0.003) were mo

219 hormones triptorelin pamoate (Trelstar) and octreotide pamoate (OncoLar).

220 ributes of AAVP-TNF particles displaying the octreotide peptide motif (termed Oct-AAVP-TNF) were conf

221 lkyne click (CuAAC) reaction for labeling an octreotide peptide with far-red emitting coumarin-based

222 TERLI group) and 22 to receive midodrine and octreotide plus albumin (MID/OCT group).

223 nificantly more effective than midodrine and octreotide plus albumin in improving renal function in p

224 rlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of HRS in a ran

225 /- 0.8 mmol/l) (P < 0.001) at 180 min during octreotide plus glucagon in doses of 0.5, 1.0, and 2.0 n

226 es with octreotide alone; the remainder with octreotide plus prednisone).

227 /- 0.1 mmol/l) (P < 0.001) at 180 min during octreotide plus saline and were 104 +/- 16 mg/dl (5.8 +/

228 However, whether octreotide preconditioning could also reduce acute kidne

229 Octreotide pretreatment significantly preserved renal fu

230 Twelve patients (24%) who received secondary octreotide prophylaxis developed another GI bleed, where

231 midgut NETs with long-acting and repeatable octreotide, PRRT reduced the hazard of disease progressi

232 Our results indicate that octreotide reduced renal injury after HIR due to its ind

233 In vivo blocking studies with octreotide reduced tumor uptake of (64)Cu-MMC(IR800)-TOC

234 servative therapy with diet modification and octreotide remain the standard initial approach.

235 obacter felis for 2 mo with the SOM analogue octreotide resolved the inflammation.

236 32%, 45%, 21%, and 2% of patients receiving octreotide, respectively, and in 51%, 24%, 21%, and 5% o

237 le symptomatic suprasellar hemangioblastoma, octreotide resulted in tumor volume reduction, symptom s

238 e and after receiving long-acting repeatable octreotide (Sandostatin LAR) were included in the study.

239 usive histology; three patients had negative octreotide scan).

240 radiotherapy, uptake on the [(111)In-DTPA(0)]octreotide scan, tumor load, grade 3-4 hematologic toxic

241 e alone has modest activity in patients with octreotide scan-positive thymoma.

242 , SSTR PET/CT was performed after an (111)In-Octreotide scan.

243 PET/CT even when performed after an (111)In-Octreotide scan.

244 Octreotide scanning has a sensitivity of primary tumor d

245 -diethylenetriaminepentaacetic acid-D-Phe(1)-octreotide scanning, a glomerular filtration rate of 80

246 d (111)In-diethylenetriaminepentaacetic acid-octreotide scans have greatly increased the sensitivity

247 significantly more lesions than (111)In-DTPA-octreotide scintigraphy (P < 0.001).

248 In-diethylenetriaminepentaacetic acid (DTPA)-octreotide scintigraphy is currently the nuclear medicin

249 or weakly positive findings on (111)In-DTPA-octreotide scintigraphy to determine whether (68)Ga-DOTA

250 and 16 equivocal for uptake on (111)In-DTPA-octreotide scintigraphy underwent (68)Ga-DOTATATE PET.

251 Short term and long term therapy with octreotide significantly improves survival and reduces t

252 In summary, octreotide slowed the progressive increase in liver volu

253 (90)Y-Dodecanetetraacetic acid-Phe1-Tyr3-octreotide (SMT 487) is an SSTR radiopharmaceutical curr

254 tases that were positive on [(111)In-DTPA(0)]octreotide somatostatin receptor scintigraphy (SRS) befo

255 among (99m)Tc-hydrazinonicotinamide (HYNIC)-octreotide (somatostatin receptor scintigraphy [SSRS]) S

256 Paired, before and during octreotide, studies were performed in 5 acromegalics.

257 ed either 1 mL 0.9% saline or 1 mL (100 mug) octreotide subcutaneously before completing a progressiv

258 ximum of 12.5 mg thrice daily, together with octreotide subcutaneously: initial dose 100 mug thrice d

259 hase III studies, including those evaluating octreotide, sunitinib, and everolimus, has demonstrated

260 ossible rescue therapies (high-dose statins, octreotide, thalidomide, lenalidomide, and tamoxifen) we

261 in antagonist) are based on the structure of octreotide that binds to three somatostatin receptor sub

262 Although symptom relief is available with octreotide, the disease eventually becomes refractory to

263 Patients were stratified by prior octreotide therapy (stratum 1: everolimus 10 mg/d, n = 1

264 gested that quantitative SSTR imaging during octreotide therapy has the potential to determine the fr

265 are currently lacking to optimize dosing of octreotide therapy on an individual basis.

266 ay occur occasionally in patients on chronic octreotide therapy.

267 einuria (9%), and fatigue (7%); with IFN and octreotide, they included fatigue (27%), neutropenia (12

268 gut hormone response that was attenuated by octreotide, thus identifying a potential therapeutic tar

269 lthough one patient required a small dose of octreotide to maintain normoglycemia.

270 e II) clinical trials, none of whom received octreotide, to provide a context for the bleeding rates.

271 itive neuroendocrine tumors obtained from 10 octreotide-treated and 7 octreotide-naive patients.

272 In contrast, 9 of the 10 octreotide-treated tumors contained phosphorylated sst2

273 Long-acting octreotide treatment diminished (68)Ga-DOTATATE uptake i

274 Octreotide treatment of human embryo kinase-sst2 cells i

275 In a clinical trial, an empiric dose of octreotide treatment prolonged time to tumor progression

276 Furthermore, during octreotide treatment, the mean conversion of 13C-CA to 1

277 in each organ were compared before and after octreotide treatment.

278 The fully automated radiosynthesis of octreotide[Trp(2-CF(2)(18)F)] enables in vivo positron e

279 be octreotide as an effective treatment, and octreotide usage is increasing around the world for pati

280 Some authors have suggested that chronic octreotide use enhances the efficiency of radiolabeled s

281 scenarios of acute (24 h) and chronic (2 wk) octreotide use, followed by either nuclear imaging expos

282 In an animal model, SSTR occupancy by octreotide was assessed quantitatively with (68)Ga-DOTAT

283 When tested 1 h postprandially, octreotide was associated with an increased breakpoint c

284 he Cp*Rh moiety on the structure of [Tyr(3)]-octreotide was characterized by 2D NMR, resulting in the

285 and Drug Administration-approved indium 111 octreotide was followed by gamma camera imaging (planar

286 din or 4,5,6,7-tetrabromobenzotriazole, with octreotide was injected intraperitoneally from postnatal

287 Commercially obtained octreotide was modified at its N-terminus by this reagen

288 ion of alpha1-adrenergic vasoconstriction by octreotide was significantly enhanced by nitric oxide in

289 Octreotide was well tolerated; treated individuals repor

290 Trough concentrations of everolimus and octreotide were assessed.

291 sponses and calorie intake postsaline versus octreotide were compared between experimental and contro

292 stics of patients who rebled after receiving octreotide were compared with non-rebleeders.

293 NISAs and the somatostatin peptide analogue octreotide were evaluated in vitro by chemotaxis, prolif

294 Forty-four patients on stable doses of octreotide were randomly assigned to 18 weeks of treatme

295 e of MIBG (which is a false transmitter) and octreotide (which is a ligand for G protein receptor) in

296 able, as in the United States, midodrine and octreotide with albumin are used as an alternative treat

297 albumin are both superior to midodrine plus octreotide with albumin for reversal of hepatorenal synd

298 in transfected cells incubated with (111)In-octreotide with and without somatostatin-28.

299 ugh the direct synthesis of the peptide drug octreotide with excellent yield and purity.

300 of sst subtype 2 (sst2)-expressing cells to octreotide would downregulate binding of 111In-pentetreo